The angiogenic properties of human adipose-derived stem cells (HASCs) are modulated by the High mobility group box protein 1 (HMGB1)

Stefano Gentileschi, Vincenzo Arena, Giovanni Scambia, Andrea Flex, Federico Biscetti, Flavio Bertucci, Maria Candida Servillo, Flavia Angelini, Egidio Stigliano, Giuseppina Bonanno, Luca Pierelli, Raffaele Landolfi, Benedetto Sacchetti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

Peripheral arterial disease (PAD), is a major health problem. Many studies have been focused on the possibilities of treatment offered by vascular regeneration. Human adipose-derived stem cells (HASCs), multipotent CD34 + stem cells found in the stromal-vascular fraction of adipose tissues, which are capable to differentiate into multiple mesenchymal cell types. The High mobility group box 1 protein (HMGB1) is a nuclear protein involved in angiogenesis. The aim of the study was to define the role of HMGB1 in cell therapy with HASCs, in an animal model of PAD. We induced unilateral ischemia in mice and we treated them with HASCs, with the specific HMGB1-inihibitor BoxA, with HMGB1 protein, and with the specific VEGF inhibitor sFlt1, alternately or concurrently. We measured the blood flow recovery in all mice. Immunohistochemical and ELISA analyses was performed to evaluate the number of vessels and the VEGF tissue content. None auto-amputation occurred and there have been no rejection reactions to the administration of HASCs. Animals co-treated with HASCs and HMGB1 protein had an improved blood flow recovery, compared to HASCs-treated mice. The post-ischemic angiogenesis was reduced when the HMGB1 pathway was blocked or when the VEGF activity was inhibited, in mice co-treated with HASCs and HMGB1. In conclusion, the HASCs treatment can be used in a mouse model of PAD to induce post-ischemic angiogenesis, modulating angiogenesis by HMGB1. This effect is mediated by VEGF activity. Although further data are needed, these findings shed light on possible new cell treatments for patients with PAD.
Lingua originaleEnglish
pagine (da-a)349-356
Numero di pagine8
RivistaINTERNATIONAL JOURNAL OF CARDIOLOGY
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Angiogenesis
  • Cardiology and Cardiovascular Medicine
  • HASCs
  • HMGB1
  • PAD
  • VEGF

Fingerprint Entra nei temi di ricerca di 'The angiogenic properties of human adipose-derived stem cells (HASCs) are modulated by the High mobility group box protein 1 (HMGB1)'. Insieme formano una fingerprint unica.

Cita questo